Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | APP | P05067 | 1/20 | 0.67 |
| ▸ | INSR | P06213 | 1/20 | 0.67 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.67 |
| ▸ | SNCA | P37840 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23111674 | 1.00 | MAPT (0.67) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL319386 | 0.92 | MEN1 (0.77) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL29559249 | 0.92 | MEN1 (0.77) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL319385 | 0.92 | MEN1 (0.77) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL29464223 | 0.87 | SNCA (0.65) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL28707498 | 0.87 | SNCA (0.65) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL537848 | 0.86 | MAPT (0.69) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL31063726 | 0.86 | MAPT (0.69) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL537849 | 0.86 | MAPT (0.69) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL8034150 | 0.84 | SNCA (0.78) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136718-A1 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | Alzeca Biosciences, LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20210063411-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MED SYST INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10883999-B2 | Detecting targets using mass tags and mass spectrometry | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200261605-A1 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | Alzeca Biosciences, LLC | 2020-08-20 | — | — | US | disclosed |
| US-20190004061-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MED SYST INC (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2588144-B1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MED SYST INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20160139143-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160139143-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9291597-B2 | Detecting targets using mass tags and mass spectrometry | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9291597-B2 | Detecting targets using mass tags and mass spectrometry | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20130122516-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130122516-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2012003478-A2 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136718-A1 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | APBA1, LYPLAL1, APOL1 | MAPT 253/4885MEN1 3983/4885KMT2A 3659/4885 |
| US-20200261605-A1 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | APBA1, LYPLAL1, APOL1 | MAPT 253/4885MEN1 3983/4885KMT2A 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.